Join
Live feed
·
PRReleasevia Quantisnow
Pliant Therapeutics Inc. logo

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

ByQuantisnow·Wall Street's wire, on your screen.
PLRX· Pliant Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PLRX (Pliant Therapeutics Inc.) and more on Quantisnow.